41
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A high level of the phosphate-regulating hormone fibroblast growth factor 23 (FGF-23) is associated with mortality in patients with end-stage renal disease, but little is known about its relationship with adverse outcomes in the much larger population of patients with earlier stages of chronic kidney disease.

          Related collections

          Author and article information

          Journal
          JAMA
          JAMA
          American Medical Association (AMA)
          1538-3598
          0098-7484
          Jun 15 2011
          : 305
          : 23
          Affiliations
          [1 ] Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine, 1120 NW 14th St, Miami, FL 33136, USA.
          Article
          305/23/2432 NIHMS304949
          10.1001/jama.2011.826
          3124770
          21673295
          1b03866e-1987-4f90-8ec9-ab854d3b1022
          History

          Comments

          Comment on this article